Skip to main content

Marketing authorisation for leniolisib in the European Economic Area is anticipated in H1 2023.

“EMA’s validation for review of our MAA under an accelerated assessment pathway highlights Pharming’s ongoing commitment to advance leniolisib as a targeted treatment for adults and adolescents 12 years of age or older with APDS."

- Anurag Relan, MD, MPH | Chief Medical Officer
Cookies: This website uses cookies Check the cookies page for more information Accept Decline